Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of upgrading from bortezomib to carfilzomib in newly diagnosed multiple myeloma
ChiCTR2500101593Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Apr 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by General Hospital of the Northern Theater Command. Primary endpoints: MRD negative, Overall response rate and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500101593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101593.